High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Cranefield, DJ en
dc.contributor.author Odd, DE en
dc.contributor.author Harding, Jane en
dc.contributor.author Teele, RL en
dc.date.accessioned 2018-10-03T23:21:38Z en
dc.date.issued 2004 en
dc.identifier.issn 0301-0449 en
dc.identifier.uri http://hdl.handle.net/2292/38657 en
dc.description.abstract The use of postnatal corticosteroids to treat or prevent chronic lung disease is common in very preterm infants. Medullary nephrocalcinosis has been noted as a possible side effect.This prospective study was designed to assess the incidence of nephrocalcinosis in extremely preterm infants exposed to dexamethasone.A prospective study of extremely preterm infants, recruited to a randomized trial of dexamethasone treatment for chronic lung disease, was initiated. Infants had US of the renal tract scheduled on entry into the study, at day 28 and at discharge or at the corrected gestational age of 36 weeks.Thirty-three infants were enrolled in the study. Birth weight ranged between 440 and 990 g and gestation between 24 and 28 weeks. Nine infants died and six had incomplete data. Because there was no difference in incidence of calcification between those on the short course and those on the long course of dexamethasone, analysis was made on the entire cohort. One infant had nephrocalcinosis at the time of the initial US examination on day 26 of life. By day 28, nephrocalcinosis was present in 31% of those with complete data. By discharge, or corrected gestational age of 36 weeks, US evidence of nephrocalcinosis was present in 15 (83%) of 18 infants. All infants had at least one course of an aminoglycoside antibiotic during the study. All infants had parenteral nutrition. Only four infants received furosemide more regularly than single doses. The longest course was 10 days, received by an infant who did not develop nephrocalcinosis.The incidence of nephrocalcinosis is high in this group of sick, extremely preterm infants. Dexamethasone may be a factor in the development of nephrocalcinosis. Future research should focus on the natural history of nephrocalcinosis in extremely preterm infants. en
dc.publisher Springer Verlag en
dc.relation.ispartofseries Pediatric Radiology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone en
dc.type Journal Article en
dc.identifier.doi 10.1007/s00247-003-1090-7 en
pubs.issue 2 en
pubs.begin-page 138 en
pubs.volume 34 en
dc.rights.holder Copyright: The author en
dc.identifier.pmid 14624322 en
pubs.end-page 142 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 199387 en
pubs.org-id Liggins Institute en
pubs.org-id LiFePATH en
pubs.record-created-at-source-date 2011-01-14 en
pubs.dimensions-id 14624322 en

Full text options

Full text for this item is not available in ResearchSpace.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace

Advanced Search